anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Quote

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 18,554
Current window 14,911-14,940
Pages 619
Rows per page 30
Component: Quoteclear collectionreset all
18 30 60

Component

14,911-14,940 of 18,554

filter-aware
52
The slide uses historical news headlines to illustrate the regulatory and safety failure of the drug Seldane.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
53
The slide uses a historical precedent (Seldane/terfenadine recall) to frame the severity of a current drug's (pitolisant) safety profile, highlighting specific death and exposure statistics.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
54
The slide uses a bar chart to compare reporting rates per million daily doses, with specific focus on drugs withdrawn from the market due to cardiac safety concerns.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
56
The slide uses a direct quote from scientific literature to establish a causal link between the drug's mechanism and its side effects.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
57
The slide uses a specific research paper abstract to validate the claim of inherent cardiotoxicity.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
58
Includes a visual comparison of pharmacophore models and a specific reference to ABT-239.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
61
The slide uses a combination of narrative text and a supporting data table to argue that certain structural features are predictive of drug safety risks.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
62
The slide highlights the specific chemical challenge of nitrogen basicity in piperidine rings and the potential for fluorine to modulate pKa for improved safety.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
63
The slide uses a screenshot of a blog post with red underlines to emphasize key quotes about hERG activity and piperidine.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
65
The slide uses a 'before-after' or 'evidence-based' contradiction structure to undermine the value of the licensed asset.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
66
The slide uses a 'quote-and-commentary' structure to expose potential corporate malfeasance or negligence.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
67
The slide uses historical publication data to cast doubt on the quality of the drug pitolisant by highlighting that the inventor prioritized other compounds.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
70
The slide uses a 'villain' framing by highlighting the industry-wide failure of a specific drug class.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
74
The slide uses a combination of narrative summary and a direct excerpt from a scientific review paper to validate the difficulty of the target.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
75
The slide uses a 'before-after' narrative structure to show that shifting chemical scaffolds did not solve the underlying safety issues in H3 receptor drug development.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
76
The slide uses excerpts from scientific literature to frame the technical hurdles in CNS drug development.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
77
The slide uses a 'villain critique' approach by leveraging a peer's own research to undermine the target's (Bioprojet/pitolisant) technology.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
79
The slide uses a forensic literature review approach to highlight historical concerns about the drug's safety profile (cardiotoxicity, bioavailability, etc.) that were allegedly ignored or suppressed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
80
The slide uses a primary text block to summarize the contradiction, followed by a direct excerpt from a 2008 paper as evidence.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
81
The slide uses a direct quote from a scientific paper to undermine the viability of the drug candidate mentioned in the lower text block.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
83
The slide uses a Q&A format to present expert testimony as evidence of product failure.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
84
The slide uses a Q&A transcript format to build a case against the efficacy of pitolisant based on historical failures at Abbott.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
86
The slide uses a Q&A format to frame the failure as a known, expected outcome rather than a surprise, highlighting the difficulty of the H3 class.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
87
The slide uses a Q&A transcript format to validate the thesis that the drug class is fundamentally flawed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
89
The slide uses expert testimony to undermine the credibility of the company (Bioprojet) and the drug (pitolisant).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
90
The slide uses a Q&A transcript format to validate a negative thesis about the viability of H3 receptor programs.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
91
The slide uses a Q&A transcript format to validate the thesis that the H3 receptor class is fundamentally flawed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
92
The slide uses a Q&A transcript format to highlight a specific failure case study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
93
The slide uses a Q&A format to build a case against the safety of a drug program.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
94
The slide uses a Q&A transcript format to corroborate previous claims about drug instability and poor blood-brain barrier penetration.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit